Latest current cash for SBHMY: $15B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), SBHMY shows a current cash of $15B. That compares with $11B in the prior-year period — up 34.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SBHMY's current cash is now $15B (was $11B) — a 34.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sino Biopharmaceutical is outperforming or lagging.
Tracking SBHMY's current cash over time shows whether Sino Biopharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $15B That compares with $11B in the prior-year period — up 34.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has Sino Biopharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $15B) with ownership activity and broader fundamentals.
Sino Biopharmaceutical's current cash is $15B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.